Galera Therapeutics, Inc. (GRTX)
USD 0.02
(8.11%)
USD 0.02
(8.11%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 151.04 Million USD | 8.17% |
| 2022 | 139.63 Million USD | 317252.27% |
| 2021 | 44 Thousand USD | -85.14% |
| 2020 | 296 Thousand USD | -44.57% |
| 2019 | 534 Thousand USD | -97.36% |
| 2018 | 20.22 Million USD | 0.0% |
| 2017 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 1.03 Million USD | -100.0% |
| 2024 Q1 | 151.04 Million USD | 0.0% |
| 2023 Q4 | 151.04 Million USD | 12977.84% |
| 2023 Q2 | 1.19 Million USD | -99.17% |
| 2023 Q1 | 143.85 Million USD | 3.02% |
| 2023 FY | 151.04 Million USD | 8.17% |
| 2023 Q3 | 1.15 Million USD | -3.19% |
| 2022 Q3 | 136.31 Million USD | 2.44% |
| 2022 Q1 | 130.36 Million USD | 296186.36% |
| 2022 FY | 139.63 Million USD | 317252.27% |
| 2022 Q4 | 139.63 Million USD | 2.44% |
| 2022 Q2 | 133.06 Million USD | 2.07% |
| 2021 Q1 | 235 Thousand USD | -20.61% |
| 2021 FY | 44 Thousand USD | -85.14% |
| 2021 Q4 | 44 Thousand USD | -60.0% |
| 2021 Q3 | 110 Thousand USD | -36.05% |
| 2021 Q2 | 172 Thousand USD | -26.81% |
| 2020 Q3 | 356 Thousand USD | -14.01% |
| 2020 Q2 | 414 Thousand USD | -12.29% |
| 2020 Q1 | 472 Thousand USD | -11.61% |
| 2020 FY | 296 Thousand USD | -44.57% |
| 2020 Q4 | 296 Thousand USD | -16.85% |
| 2019 FY | 534 Thousand USD | -97.36% |
| 2019 Q3 | 604 Thousand USD | -10.91% |
| 2019 Q2 | 678 Thousand USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 Q4 | 534 Thousand USD | -11.59% |
| 2018 Q4 | - USD | 0.0% |
| 2018 FY | 20.22 Million USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| America Great Health | 1.12 Million USD | -13348.837% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Aridis Pharmaceuticals, Inc. | 1.29 Million USD | -11591.099% |
| Biora Therapeutics, Inc. | 43.73 Million USD | -245.365% |
| Bio-Path Holdings, Inc. | 10 Thousand USD | -1510390.0% |
| Better Therapeutics, Inc. | 10.34 Million USD | -1359.693% |
| Calithera Biosciences, Inc. | 136 Thousand USD | -110965.441% |
| Comera Life Sciences Holdings, Inc. | 120.3 Thousand USD | -125458.179% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | - USD | -Infinity% |
| Eloxx Pharmaceuticals, Inc. | 8.69 Million USD | -1637.793% |
| Evelo Biosciences, Inc. | 48.87 Million USD | -209.026% |
| Evolutionary Genomics, Inc. | 3.74 Million USD | -3934.701% |
| Finch Therapeutics Group, Inc. | 28.4 Million USD | -431.806% |
| Innovation1 Biotech Inc. | 218.99 Thousand USD | -68872.461% |
| Kiromic BioPharma, Inc. | 911.5 Thousand USD | -16471.476% |
| Molecular Templates, Inc. | 9.74 Million USD | -1450.493% |
| Navidea Biopharmaceuticals, Inc. | 1.87 Million USD | -7970.085% |
| NexImmune, Inc. | - USD | -Infinity% |
| Orgenesis Inc. | 19.06 Million USD | -692.201% |
| Panbela Therapeutics, Inc. | 4.19 Million USD | -3501.55% |
| Point of Care Nano-Technology, Inc. | - USD | -Infinity% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| Sorrento Therapeutics, Inc. | 104.33 Million USD | -44.769% |
| Statera Biopharma, Inc. | 11.43 Million USD | -1221.382% |
| TRACON Pharmaceuticals, Inc. | 732 Thousand USD | -20535.109% |
| Trevena, Inc. | 35.23 Million USD | -328.715% |
| Vaxxinity, Inc. | 13.26 Million USD | -1038.961% |
| Vaccinex, Inc. | 26 Thousand USD | -580857.692% |
| Vicapsys Life Sciences, Inc. | - USD | -Infinity% |
| Viracta Therapeutics, Inc. | - USD | -Infinity% |
| ZIVO Bioscience, Inc. | - USD | -Infinity% |